WallStSmart
LRMR

Larimar Therapeutics Inc

NASDAQ: LRMR · HEALTHCARE · BIOTECHNOLOGY

$4.13
-3.65% today

Updated 2026-06-05

Market cap
$329.31M
P/E ratio
P/S ratio
EPS (TTM)
$-2.12
Dividend yield
52W range
$2 – $6
Volume
1.6M

Larimar Therapeutics Inc (LRMR) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item201120122013201420152016201720182019202020212022202320242025
Operating cash flow$-12.27M$-13.59M$-15.00M$-28.24M$-59.55M$-51.98M$-43.78M$-51.49M$-22.70M$-42.20M$-42.10M$-27.57M$-33.46M$-70.76M$-113.20M
Capital expenditures$35000.00$2000.00$17000.00$58000.00$595000.00$660000.00$55000.00$108000.00$83000.00$62000.00$333000.00$100000.00$163999.00$515000.00$91000.00
Depreciation
Stock-based comp$1.55M$8.58M$173000.00$129000.00$2.16M$5.47M$6.62M$7.62M$8.80M$7.00M
Free cash flow$-12.31M$-13.59M$-15.02M$-28.30M$-60.15M$-52.63M$-43.84M$-51.59M$-22.78M$-42.26M$-42.44M$-27.67M$-33.62M$-71.28M$-113.29M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash$68.48M$-43.27M

Frequently asked questions

How much free cash flow does LRMR generate?

LRMR produced $-113.29M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is LRMR's balance sheet healthy?

LRMR holds $85.41M in cash and equivalents against — in long-term debt, on $78.08M of shareholder equity. That debt is best read against the cash flow the business throws off each year.